Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy

Tharimmune's stock has surged by 30% following a significant $540 million capital raise aimed at developing a treasury strategy centered around Canton Coin. This pivot into digital assets, supported by notable investors like DRW and Liberty City Ventures, highlights the growing intersection of biotechnology and cryptocurrency. This move not only strengthens Tharimmune's financial position but also positions it at the forefront of innovation in the biotech sector, potentially attracting more investors and interest in its future projects.